FDA Approves Besivance to Treat Conjunctivitis

The U.S. Food and Drug Administration (FDA) has granted additional labeling indications for Bausch + Lomb's Besivance (besifloxacin ophthalmic suspension) 0.6 percent eyedrop. It is now indicated to treat bacterial conjunctivitis infections caused by susceptible isolates of Pseudomonas aeruginosa.